Automated GMP production and long‐term experience in radiosynthesis of CB1 tracer [18F]FMPEP‐d2

Here, we describe the development of an in‐house‐built device for the fully automated multistep synthesis of the cannabinoid CB1 receptor imaging tracer (3R,5R)‐5‐(3‐([18F]fluoromethoxy‐d2)phenyl)‐3‐(((R)‐1‐phenylethyl)amino)‐1‐(4‐(trifluoromethyl)phenyl)pyrrolidin‐2‐one ([18F]FMPEP‐d2), following g...

Full description

Saved in:
Bibliographic Details
Published in:Journal of labelled compounds & radiopharmaceuticals 2020-07, Vol.63 (9), p.408-418
Main Authors: Lahdenpohja, Salla, Keller, Thomas, Forsback, Sarita, Viljanen, Tapio, Kokkomäki, Esa, Kivelä, Riikka V., Bergman, Jörgen, Solin, Olof, Kirjavainen, Anna K.
Format: Article
Language:English
Subjects:
Alkylation
Automation
Cannabinoid CB1 receptors
Cleanrooms
Fluorination
fluoroalkylation
GMP
Good Manufacturing Practice
High-performance liquid chromatography
nucleophilic 18F‐fluorination
positron emission tomography
Purification
Radiochemistry
radiopharmaceutical
Synthesis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 418
container_issue 9
container_start_page 408
container_title Journal of labelled compounds & radiopharmaceuticals
container_volume 63
creator Lahdenpohja, Salla
Keller, Thomas
Forsback, Sarita
Viljanen, Tapio
Kokkomäki, Esa
Kivelä, Riikka V.
Bergman, Jörgen
Solin, Olof
Kirjavainen, Anna K.
description Here, we describe the development of an in‐house‐built device for the fully automated multistep synthesis of the cannabinoid CB1 receptor imaging tracer (3R,5R)‐5‐(3‐([18F]fluoromethoxy‐d2)phenyl)‐3‐(((R)‐1‐phenylethyl)amino)‐1‐(4‐(trifluoromethyl)phenyl)pyrrolidin‐2‐one ([18F]FMPEP‐d2), following good manufacturing practices. The device is interfaced to a HPLC and a sterile filtration unit in a clean room hot cell. The synthesis involves the nucleophilic 18F‐fluorination of an alkylating agent and its GC purification, the subsequent 18F‐fluoroalkylation of a precursor molecule, the semipreparative HPLC purification of the 18F‐fluoroalkylated product, and its formulation for injection. We have optimized the duration and temperature of the 18F‐fluoroalkylation reaction and addressed the radiochemical stability of the formulated product. During the past 5 years (2013–2018), we have performed a total of 149 syntheses for clinical use with a 90% success rate. The activity yield of the formulated product has been 1.0 ± 0.4 GBq starting from 11 ± 2 GBq and the molar activity 600 ± 300 GBq/μmol at the end of synthesis. [18F]FMPEP‐d2 production at Turku PET Centre during 2013–2018: 149 syntheses for clinical use 90% success rate 16 ± 6% RCY 1.0 ± 0.4 GBq activity yield 600 ± 300 GBq/μmol
doi_str_mv 10.1002/jlcr.3845
format article
fullrecord <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_proquest_journals_2426067050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2426067050</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1735-ab585c1c1a4f1f890736aca74e8e360d69890edd7e1132a17d3fe8ab49589d143</originalsourceid><addsrcrecordid>eNotkEFOwzAQRS0EEqWw4AaWWId6YidxliVqC6gVFYIVQpZrTyBVmgTHEXTHETgjJyFRWc1o5v_5mkfIJbBrYCycbEvjrrkU0REZAUvTALgQx2TEeBwGQjJ-Ss7adstYvxNiRMy08_VOe7R0sVrTxtW2M76oK6orS8u6evv9_vHodhS_GnQFVgZpUVGnbVG3-8q_Y1u0tM5pdgPUO23Q0ReQ89f5aj1b92YbnpOTXJctXvzXMXmez56y22D5sLjLpsuggYRHgd5EMjJgQIsccpmyhMfa6ESgRB4zG6f9DK1NEICHGhLLc5R6I9JIphYEH5Orw93-i48OW6-2deeqPlKFIoxZnLCI9arJQfVZlLhXjSt22u0VMDUAVANANQBU98vscWj4H_KIZog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2426067050</pqid></control><display><type>article</type><title>Automated GMP production and long‐term experience in radiosynthesis of CB1 tracer [18F]FMPEP‐d2</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Lahdenpohja, Salla ; Keller, Thomas ; Forsback, Sarita ; Viljanen, Tapio ; Kokkomäki, Esa ; Kivelä, Riikka V. ; Bergman, Jörgen ; Solin, Olof ; Kirjavainen, Anna K.</creator><creatorcontrib>Lahdenpohja, Salla ; Keller, Thomas ; Forsback, Sarita ; Viljanen, Tapio ; Kokkomäki, Esa ; Kivelä, Riikka V. ; Bergman, Jörgen ; Solin, Olof ; Kirjavainen, Anna K.</creatorcontrib><description>Here, we describe the development of an in‐house‐built device for the fully automated multistep synthesis of the cannabinoid CB1 receptor imaging tracer (3R,5R)‐5‐(3‐([18F]fluoromethoxy‐d2)phenyl)‐3‐(((R)‐1‐phenylethyl)amino)‐1‐(4‐(trifluoromethyl)phenyl)pyrrolidin‐2‐one ([18F]FMPEP‐d2), following good manufacturing practices. The device is interfaced to a HPLC and a sterile filtration unit in a clean room hot cell. The synthesis involves the nucleophilic 18F‐fluorination of an alkylating agent and its GC purification, the subsequent 18F‐fluoroalkylation of a precursor molecule, the semipreparative HPLC purification of the 18F‐fluoroalkylated product, and its formulation for injection. We have optimized the duration and temperature of the 18F‐fluoroalkylation reaction and addressed the radiochemical stability of the formulated product. During the past 5 years (2013–2018), we have performed a total of 149 syntheses for clinical use with a 90% success rate. The activity yield of the formulated product has been 1.0 ± 0.4 GBq starting from 11 ± 2 GBq and the molar activity 600 ± 300 GBq/μmol at the end of synthesis. [18F]FMPEP‐d2 production at Turku PET Centre during 2013–2018: 149 syntheses for clinical use 90% success rate 16 ± 6% RCY 1.0 ± 0.4 GBq activity yield 600 ± 300 GBq/μmol</description><identifier>ISSN: 0362-4803</identifier><identifier>EISSN: 1099-1344</identifier><identifier>DOI: 10.1002/jlcr.3845</identifier><language>eng</language><publisher>Bognor Regis: Wiley Subscription Services, Inc</publisher><subject>Alkylation ; Automation ; Cannabinoid CB1 receptors ; Cleanrooms ; Fluorination ; fluoroalkylation ; GMP ; Good Manufacturing Practice ; High-performance liquid chromatography ; nucleophilic 18F‐fluorination ; positron emission tomography ; Purification ; Radiochemistry ; radiopharmaceutical ; Synthesis</subject><ispartof>Journal of labelled compounds &amp; radiopharmaceuticals, 2020-07, Vol.63 (9), p.408-418</ispartof><rights>2020 The Authors. Journal of Labelled Compounds and Radiopharmaceuticals published by John Wiley &amp; Sons Ltd</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-3981-2973 ; 0000-0003-2456-5009 ; 0000-0003-1026-4029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Lahdenpohja, Salla</creatorcontrib><creatorcontrib>Keller, Thomas</creatorcontrib><creatorcontrib>Forsback, Sarita</creatorcontrib><creatorcontrib>Viljanen, Tapio</creatorcontrib><creatorcontrib>Kokkomäki, Esa</creatorcontrib><creatorcontrib>Kivelä, Riikka V.</creatorcontrib><creatorcontrib>Bergman, Jörgen</creatorcontrib><creatorcontrib>Solin, Olof</creatorcontrib><creatorcontrib>Kirjavainen, Anna K.</creatorcontrib><title>Automated GMP production and long‐term experience in radiosynthesis of CB1 tracer [18F]FMPEP‐d2</title><title>Journal of labelled compounds &amp; radiopharmaceuticals</title><description>Here, we describe the development of an in‐house‐built device for the fully automated multistep synthesis of the cannabinoid CB1 receptor imaging tracer (3R,5R)‐5‐(3‐([18F]fluoromethoxy‐d2)phenyl)‐3‐(((R)‐1‐phenylethyl)amino)‐1‐(4‐(trifluoromethyl)phenyl)pyrrolidin‐2‐one ([18F]FMPEP‐d2), following good manufacturing practices. The device is interfaced to a HPLC and a sterile filtration unit in a clean room hot cell. The synthesis involves the nucleophilic 18F‐fluorination of an alkylating agent and its GC purification, the subsequent 18F‐fluoroalkylation of a precursor molecule, the semipreparative HPLC purification of the 18F‐fluoroalkylated product, and its formulation for injection. We have optimized the duration and temperature of the 18F‐fluoroalkylation reaction and addressed the radiochemical stability of the formulated product. During the past 5 years (2013–2018), we have performed a total of 149 syntheses for clinical use with a 90% success rate. The activity yield of the formulated product has been 1.0 ± 0.4 GBq starting from 11 ± 2 GBq and the molar activity 600 ± 300 GBq/μmol at the end of synthesis. [18F]FMPEP‐d2 production at Turku PET Centre during 2013–2018: 149 syntheses for clinical use 90% success rate 16 ± 6% RCY 1.0 ± 0.4 GBq activity yield 600 ± 300 GBq/μmol</description><subject>Alkylation</subject><subject>Automation</subject><subject>Cannabinoid CB1 receptors</subject><subject>Cleanrooms</subject><subject>Fluorination</subject><subject>fluoroalkylation</subject><subject>GMP</subject><subject>Good Manufacturing Practice</subject><subject>High-performance liquid chromatography</subject><subject>nucleophilic 18F‐fluorination</subject><subject>positron emission tomography</subject><subject>Purification</subject><subject>Radiochemistry</subject><subject>radiopharmaceutical</subject><subject>Synthesis</subject><issn>0362-4803</issn><issn>1099-1344</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNotkEFOwzAQRS0EEqWw4AaWWId6YidxliVqC6gVFYIVQpZrTyBVmgTHEXTHETgjJyFRWc1o5v_5mkfIJbBrYCycbEvjrrkU0REZAUvTALgQx2TEeBwGQjJ-Ss7adstYvxNiRMy08_VOe7R0sVrTxtW2M76oK6orS8u6evv9_vHodhS_GnQFVgZpUVGnbVG3-8q_Y1u0tM5pdgPUO23Q0ReQ89f5aj1b92YbnpOTXJctXvzXMXmez56y22D5sLjLpsuggYRHgd5EMjJgQIsccpmyhMfa6ESgRB4zG6f9DK1NEICHGhLLc5R6I9JIphYEH5Orw93-i48OW6-2deeqPlKFIoxZnLCI9arJQfVZlLhXjSt22u0VMDUAVANANQBU98vscWj4H_KIZog</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Lahdenpohja, Salla</creator><creator>Keller, Thomas</creator><creator>Forsback, Sarita</creator><creator>Viljanen, Tapio</creator><creator>Kokkomäki, Esa</creator><creator>Kivelä, Riikka V.</creator><creator>Bergman, Jörgen</creator><creator>Solin, Olof</creator><creator>Kirjavainen, Anna K.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><orcidid>https://orcid.org/0000-0003-3981-2973</orcidid><orcidid>https://orcid.org/0000-0003-2456-5009</orcidid><orcidid>https://orcid.org/0000-0003-1026-4029</orcidid></search><sort><creationdate>202007</creationdate><title>Automated GMP production and long‐term experience in radiosynthesis of CB1 tracer [18F]FMPEP‐d2</title><author>Lahdenpohja, Salla ; Keller, Thomas ; Forsback, Sarita ; Viljanen, Tapio ; Kokkomäki, Esa ; Kivelä, Riikka V. ; Bergman, Jörgen ; Solin, Olof ; Kirjavainen, Anna K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1735-ab585c1c1a4f1f890736aca74e8e360d69890edd7e1132a17d3fe8ab49589d143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alkylation</topic><topic>Automation</topic><topic>Cannabinoid CB1 receptors</topic><topic>Cleanrooms</topic><topic>Fluorination</topic><topic>fluoroalkylation</topic><topic>GMP</topic><topic>Good Manufacturing Practice</topic><topic>High-performance liquid chromatography</topic><topic>nucleophilic 18F‐fluorination</topic><topic>positron emission tomography</topic><topic>Purification</topic><topic>Radiochemistry</topic><topic>radiopharmaceutical</topic><topic>Synthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lahdenpohja, Salla</creatorcontrib><creatorcontrib>Keller, Thomas</creatorcontrib><creatorcontrib>Forsback, Sarita</creatorcontrib><creatorcontrib>Viljanen, Tapio</creatorcontrib><creatorcontrib>Kokkomäki, Esa</creatorcontrib><creatorcontrib>Kivelä, Riikka V.</creatorcontrib><creatorcontrib>Bergman, Jörgen</creatorcontrib><creatorcontrib>Solin, Olof</creatorcontrib><creatorcontrib>Kirjavainen, Anna K.</creatorcontrib><collection>Wiley Online Library Open Access</collection><jtitle>Journal of labelled compounds &amp; radiopharmaceuticals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lahdenpohja, Salla</au><au>Keller, Thomas</au><au>Forsback, Sarita</au><au>Viljanen, Tapio</au><au>Kokkomäki, Esa</au><au>Kivelä, Riikka V.</au><au>Bergman, Jörgen</au><au>Solin, Olof</au><au>Kirjavainen, Anna K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Automated GMP production and long‐term experience in radiosynthesis of CB1 tracer [18F]FMPEP‐d2</atitle><jtitle>Journal of labelled compounds &amp; radiopharmaceuticals</jtitle><date>2020-07</date><risdate>2020</risdate><volume>63</volume><issue>9</issue><spage>408</spage><epage>418</epage><pages>408-418</pages><issn>0362-4803</issn><eissn>1099-1344</eissn><abstract>Here, we describe the development of an in‐house‐built device for the fully automated multistep synthesis of the cannabinoid CB1 receptor imaging tracer (3R,5R)‐5‐(3‐([18F]fluoromethoxy‐d2)phenyl)‐3‐(((R)‐1‐phenylethyl)amino)‐1‐(4‐(trifluoromethyl)phenyl)pyrrolidin‐2‐one ([18F]FMPEP‐d2), following good manufacturing practices. The device is interfaced to a HPLC and a sterile filtration unit in a clean room hot cell. The synthesis involves the nucleophilic 18F‐fluorination of an alkylating agent and its GC purification, the subsequent 18F‐fluoroalkylation of a precursor molecule, the semipreparative HPLC purification of the 18F‐fluoroalkylated product, and its formulation for injection. We have optimized the duration and temperature of the 18F‐fluoroalkylation reaction and addressed the radiochemical stability of the formulated product. During the past 5 years (2013–2018), we have performed a total of 149 syntheses for clinical use with a 90% success rate. The activity yield of the formulated product has been 1.0 ± 0.4 GBq starting from 11 ± 2 GBq and the molar activity 600 ± 300 GBq/μmol at the end of synthesis. [18F]FMPEP‐d2 production at Turku PET Centre during 2013–2018: 149 syntheses for clinical use 90% success rate 16 ± 6% RCY 1.0 ± 0.4 GBq activity yield 600 ± 300 GBq/μmol</abstract><cop>Bognor Regis</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/jlcr.3845</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-3981-2973</orcidid><orcidid>https://orcid.org/0000-0003-2456-5009</orcidid><orcidid>https://orcid.org/0000-0003-1026-4029</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0362-4803
ispartof Journal of labelled compounds & radiopharmaceuticals, 2020-07, Vol.63 (9), p.408-418
issn 0362-4803
1099-1344
language eng
recordid cdi_proquest_journals_2426067050
source Wiley-Blackwell Read & Publish Collection
subjects Alkylation
Automation
Cannabinoid CB1 receptors
Cleanrooms
Fluorination
fluoroalkylation
GMP
Good Manufacturing Practice
High-performance liquid chromatography
nucleophilic 18F‐fluorination
positron emission tomography
Purification
Radiochemistry
radiopharmaceutical
Synthesis
title Automated GMP production and long‐term experience in radiosynthesis of CB1 tracer [18F]FMPEP‐d2
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A11%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Automated%20GMP%20production%20and%20long%E2%80%90term%20experience%20in%20radiosynthesis%20of%20CB1%20tracer%20%5B18F%5DFMPEP%E2%80%90d2&rft.jtitle=Journal%20of%20labelled%20compounds%20&%20radiopharmaceuticals&rft.au=Lahdenpohja,%20Salla&rft.date=2020-07&rft.volume=63&rft.issue=9&rft.spage=408&rft.epage=418&rft.pages=408-418&rft.issn=0362-4803&rft.eissn=1099-1344&rft_id=info:doi/10.1002/jlcr.3845&rft_dat=%3Cproquest_wiley%3E2426067050%3C/proquest_wiley%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p1735-ab585c1c1a4f1f890736aca74e8e360d69890edd7e1132a17d3fe8ab49589d143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2426067050&rft_id=info:pmid/&rfr_iscdi=true